Carmignac Gestion Purchases Shares of 448,606 Organon & Co. $OGN

Key Points

• Carmignac Gestion acquired 448,606 Organon & Co. shares in the second quarter, worth approximately $6.07 million and representing about 0.17% of the company. Institutional investors collectively own 77.43% of Organon stock.
• Analyst sentiment remains cautious: Weiss Ratings downgraded the stock to “hold (c-),” while the broader consensus is “Reduce,” with five Holds and two Sells and a $11.40 average price target.
• Organon shares recently traded near their 52-week high at $13.77. The company declared a quarterly dividend of $0.02 per share, equivalent to an annualized dividend of $0.08 and a 0.6% yield.

Carmignac Gestion acquired a new stake in Organon & Co. (NYSE:OGN - Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 448,606 shares of the company's stock, valued at approximately $6,074,000. Carmignac Gestion owned approximately 0.17% of Organon & Co. as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Allied Private Wealth LLC bought a new stake in Organon & Co. in the second quarter valued at about $33,000. Eurizon Capital SGR S.p.A. acquired a new stake in Organon & Co. during the fourth quarter valued at approximately $44,000. Kestra Advisory Services LLC bought a new stake in shares of Organon & Co. in the 4th quarter valued at approximately $47,000. WNY Asset Management LLC bought a new stake in shares of Organon & Co. in the 1st quarter valued at approximately $64,000. Finally, Empowered Funds LLC acquired a new position in shares of Organon & Co. in the 4th quarter worth approximately $74,000. 77.43% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings lowered Organon & Co. from a "hold (c)" rating to a "hold (c-)" rating in a research note on Monday, August 3rd. Five analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Reduce" and a consensus price target of $11.40.

Organon & Co. Price Performance

NYSE:OGN traded down $0.01 on Tuesday, reaching $13.77. The stock had a trading volume of 1,629,810 shares, compared to its average volume of 5,635,393. The company has a market capitalization of $3.61 billion, a P/E ratio of 17.88, a price-to-earnings-growth ratio of 1.28 and a beta of 1.52. Organon & Co. has a 1-year low of $5.69 and a 1-year high of $13.78. The company has a quick ratio of 1.44, a current ratio of 1.95 and a debt-to-equity ratio of 8.43. The stock has a fifty day moving average price of $13.62 and a 200-day moving average price of $11.38.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $0.02 dividend. The ex-dividend date is Friday, August 14th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. Organon & Co.'s payout ratio is 10.39%.

Organon & Co. Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.